Investigational drug · Phase 2
ION337
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dravet Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ION337"
First trial start
2026
May 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ION337", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dravet Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ION337" as an intervention, largest first.
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07531745 · 32 participants (planned) · Start May 21, 2026 · Primary completion Dec 2030
Drug: ION337 · For: Dravet Syndrome
Sites: Ann Arbor, Michigan; Rochester, Minnesota; Durham, North Carolina · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Dravet Syndrome
- LP352bexicaserinPhase 34 trials
Longboard Pharmaceuticals · Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Clemizole HClEPX-100Phase 32 trials
Epygenix · Dravet Syndrome, Lennox Gastaut Syndrome
- zorevunersenSTK-001Phase 32 trials
Stoke Therapeutics, Inc · Dravet Syndrome
- ETX101Phase 23 trials
Encoded Therapeutics · Dravet Syndrome
- BMB-101Phase 22 trials
Bright Minds Biosciences Pty Ltd · Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Ionis Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.